Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 447 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Telephone-Based Rehab Program Helps People with Advanced Cancer Maintain Independence April 29, 2019 When You Have to Make Decisions for a Loved One With... November 9, 2020 Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities... September 24, 2020 Cómo puede ayudar la terapia del piso pélvico a las personas... December 13, 2022 Load more HOT NEWS FDA Approves Second CAR T-Cell Therapy for Lymphoma Qué deben saber los latinos sobre dejar de fumar y las... Treatment with Brigatinib Results in Radiographic Responses and Clinical Benefit in... ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ
